Somaglutide Analogue-1 mutant as well as expression method and application thereof
By constructing the Analogue-1 mutant of semaglutide using modular design and recombinant DNA technology, the problem of low synthesis efficiency of multiple GLP-1 peptides in existing technologies has been solved, enabling the rapid construction and efficient production of multiple bioactive peptides, reducing costs and improving production efficiency.
Patent Information
- Application Number
- CN202411383689.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-30
- Publication Date
- 2024-11-29
Smart Images

Figure CN119039419A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology, and specifically relates to a semaglutide Analogue-1 mutant and an expression method and application thereof. Background Art
[0002] With the improvement of living standards and aging, the demand for chronic disease treatment and quality of life is growing. Bioactive peptides have attracted attention for their wide range of therapeutic effects, showing great potential in many aspects, such as antibacterial, antihypertensive, antidiabetic and immunomodulatory, and are also used in beauty, skin care and body shape management. Bioactive peptides are compounds that are beneficial to life activities or have physiological effects. The "Biopep" database has reported 4710 different bioactive peptides with various functions such as anti-aging, antioxidant, anti-obesity, immunomodulatory, anti-diabetic, cholesterol-lowering and anti-cancer. Compared with traditional drugs, bioactive peptides have the advantages of stronger specific activity, low toxicity, effective at low concentrations, and easy excretion and degradation, making them an ideal choice for the treatment of chronic diseases. GLP-1 (glucagon-like peptide-1) and its analogs have performed well in the treatment of type 2 diabetes, but multiple GLP-1 peptides are the future development direction.
[0003] This design concept is based on the successful experience of single GLP-1 receptor agonists, and achieves synergistic effects and multiple therapeutic targets by combining different agonists or combining with other peptides. There is currently one approved multiple GLP-1 drug (tirpotide). The advantages of multiple GLP-1 peptides include enhanced glucose-lowering effects, improved metabolic regulation, potential cardiovascular protection, reduced dosing frequency, and personalized treatment potential. Multiple pharmaceutical companies and research institutions are developing such drugs, such as studies on the combination of GLP-1 with gastrin or GIP. These designs are expected to make progress in blood sugar control, weight management, and cardiovascular protection. In short, with the deepening of research, especially innovations in the field of GLP-1 analogs, multiple GLP-1 peptides are becoming a new focus for diabetes treatment, providing more effective blood sugar control and metabolic regulation, and bringing comprehensive health benefits to patients. Future research and clinical trials will further verify its potential and provide more advanced and personalized treatment options for diabetic patients.
[0004] There are currently two main strategies for the chemical synthesis of bioactive peptides, namely soluble phase synthesis and solid phase synthesis. In addition to these two methods, there is another chemical method, namely hybrid synthesis, which is sometimes used to produce pharmaceutical peptides. The type of protecting groups used, the ratio in the amino acid structure, and the method of deprotection are key steps in the synthesis of bioactive peptides. The most important advantage of the soluble phase synthesis method is the economic rationality and purification of each stage of the synthesis because it uses cheaper materials and equipment. In this method, the side synthesis of intermediates is present in the process of producing the desired peptide. One of the limitations of this method is the production of these intermediates.
[0005] In order to obtain the desired pure product, each initial product must undergo a change before it can enter the next stage and eventually become an active peptide. Therefore, the entire process of synthesizing active peptides in this way is often long and difficult. However, using this method, therapeutic peptides with a length of 3 to 20 amino acids have been synthesized and entered the global market. The main problems with this method are that long peptide chains are insoluble in organic solvents, the synthesis time is long, and the amount of chemical waste is large. Summary of the invention
[0006] The purpose of this section is to summarize some aspects of embodiments of the present invention and briefly introduce some preferred embodiments. Some simplifications or omissions may be made in this section and the specification abstract and the invention title of this application to avoid blurring the purpose of this section, the specification abstract and the invention title, and such simplifications or omissions cannot be used to limit the scope of the present invention.
[0007] In view of the above problems and / or the problems existing in the prior art, the present invention is proposed.
[0008] Therefore, the purpose of the present invention is to overcome the deficiencies in the prior art and provide a semaglutide Analogue-1 mutant.
[0009] To solve the above technical problems, the present invention provides the following technical solution: a semaglutide Analogue-1 mutant, wherein the single amino acid X at the second position of natural semaglutide is replaced by A, and the amino acid sequence of the semaglutide Analogue-1 mutant is shown in SEQ ID NO.2.
[0010] Another object of the present invention is to overcome the deficiencies in the prior art and provide a use of a semaglutide Analogue-1 mutant in the preparation of multiple GLP-1 bioactive peptides.
[0011] Another object of the present invention is to overcome the deficiencies in the prior art and provide a method for expressing a semaglutide Analogue-1 mutant, comprising:
[0012] The Escherichia coli is obtained by transforming a plasmid containing genes of multiple GLP-1 bioactive peptides; the genes of the multiple GLP-1 bioactive peptides are expressed by modularizing short peptides combined with multiple receptors;
[0013] Among them, the short peptide includes the semaglutide Analogue-1 mutant, and the nucleotide sequence is shown in SEQ ID NO.1; the receptor includes GIP, GCG and GLP-1, the nucleotide sequence of GIP is shown in SEQ ID NO.3, the nucleotide sequence of GCG is shown in SEQ ID NO.5, and the nucleotide sequence of GLP-1 is shown in SEQ ID NO.7.
[0014] As a preferred embodiment of the expression method of the present invention, the Escherichia coli is one or more of DH5α, JM109, W3110, and BL21 (DE3).
[0015] As a preferred embodiment of the construction method of the present invention, the short peptide further comprises liraglutide.
[0016] As a preferred embodiment of the expression method of the present invention, the genes of the multiple GLP-1 bioactive peptides include Analogues 2 to 7, the nucleotide sequence of Analogue-1 is shown in SEQ ID NO.1, the nucleotide sequence of GIP is shown in SEQ ID NO.3, the nucleotide sequence of GCG is shown in SEQ ID NO.5, the nucleotide sequence of GLP-1 is shown in SEQ ID NO.7, the nucleotide sequence of Analogue-2 is shown in SEQ ID NO.9, the nucleotide sequence of Analogue-3 is shown in SEQ ID NO.11, the nucleotide sequence of Analogue-4 is shown in SEQ ID NO.13, the nucleotide sequence of Analogue-5 is shown in SEQ ID NO.15, the nucleotide sequence of Analogue-6 is shown in SEQ ID NO.17, and the nucleotide sequence of Analogue-7 is shown in SEQ ID NO.19.
[0017] As a preferred embodiment of the expression method of the present invention, the recombination of the gene Analogues 2 to 7 of the multiple GLP-1 bioactive peptides includes:
[0018] GLP-1 and GIP are assembled into Analogue-2 through recombinant DNA technology, GLP-1 and GCG are assembled into Analogue-3 through recombinant DNA technology, GLP-1 and Analogue-1 are assembled into Analogue-4 through recombinant DNA technology, Analogue-1 and GIP are assembled into Analogue-5 through recombinant DNA technology, Analogue-1 and GCG are assembled into Analogue-6 through recombinant DNA technology, and GIP and GCG are assembled into Analogue-7.
[0019] As a preferred embodiment of the expression method of the present invention, the method comprises:
[0020] The genes Analogues 2 to 7 of the multiple GLP-1 bioactive peptides are assembled and connected to the plasmid pET-Duet-1 to construct a recombinant plasmid;
[0021] The constructed recombinant plasmids were co-transformed into E. coli BL21 (DE3) to obtain recombinant strains.
[0022] Another object of the present invention is to overcome the deficiencies in the prior art and provide a method for producing GLP-1 bioactive peptides, comprising: activating the recombinant bacteria and transferring them to a fermentation medium at an inoculum size of 1-3%, adding IPTG at a final concentration of 0.6 mM to induce protein expression when OD600 is 50 and the temperature is 30°C, adding chloramphenicol, streptomycin, ampicillin, and kanamycin as needed, culturing at 30-37°C, 200 r / min, and a cycle of 20-50 hours.
[0023] As a preferred embodiment of the method of the present invention, the fermentation medium comprises 10 g / L yeast extract, 2 g / L citric acid monohydrate, 5 g / L ammonium sulfate, 7 g / L potassium dihydrogen phosphate, 0.08 g / L ferrous sulfate heptahydrate, 0.006 g / L anhydrous calcium chloride, 10 g / L glucose, 1.5 g / L magnesium sulfate heptahydrate and 10 mL / L metal ion solution; wherein the components of the metal ion solution include 250 g / L citric acid monohydrate, 16 g / L ferric chloride hexahydrate, 0.6 g / L boric acid, 2 g / L manganese sulfate monohydrate, 0.6 g / L copper sulfate pentahydrate II, 0.6 g / L sodium molybdate dihydrate, 0.5 g / L cobalt chloride hexahydrate and 2 g / L zinc chloride.
[0024] Beneficial effects of the present invention:
[0025] 1. The present invention is based on modular combination of polypeptides with separate GPCR binding functions, thereby obtaining multiple biologically active polypeptides with multiple functions.
[0026] 2. The present invention can rapidly construct GLP-1 bioactive peptides with multiple bioactive functions without the need to redesign a single active polypeptide.
[0027] 3. The present invention can also construct polypeptides that are not limited to binding to proximal GPCR receptors.
[0028] 4. The modular polypeptide constructed by the present invention can be produced by biological synthesis, which has cost advantages and no environmental pollution. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for describing the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative labor. Among them:
[0030] Figure 1 This is a schematic diagram of module connection in Example 1.
[0031] Figure 2 The amino acid sequence diagram of GIP, GCG, GLP-1, Semaglutide and Analogue-1 in Example 1.
[0032] Figure 3 Schematic diagram of the gene synthesis of Analogues 2 to 7 in Example 2.
[0033] Figure 4 This is a gel image of the total protein expression of Analogues 2 to 7 in Example 3.
[0034] Figure 5 This is the solubility test gel image of Analogue 2 to 7 in Example 3.
[0035] Figure 6 is the cAMP accumulation of Analogue 2 in Example 4.
[0036] Figure 7 is the cAMP accumulation of Analogue 3 in Example 4.
[0037] Figure 8 is the cAMP accumulation of Analogue 4 in Example 4.
[0038] Fig. 9 is the cAMP accumulation of Analogue 5 in Example 4.
[0039] Fig.10 is the cumulative amount of cAMP of Analogue 6 in Example 4.
[0040] Fig.11 is the cAMP accumulation of Analogue 7 in Example 4.
[0041] Fig.12 is the cumulative amount of cAMP of Analogue 1 in Comparative Example 1. DETAILED DESCRIPTION
[0042] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail below in conjunction with the embodiments of the specification.
[0043] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein, and those skilled in the art may make similar generalizations without violating the connotation of the present invention, so the present invention is not limited to the specific embodiments disclosed below. Secondly, the "one embodiment" or "embodiment" referred to herein refers to a specific feature, structure or characteristic that may be included in at least one implementation of the present invention. The "in one embodiment" that appears in different places in this specification does not all refer to the same embodiment, nor is it a separate or selective embodiment that is mutually exclusive with other embodiments.
[0044] The raw materials and reagents used in the present invention: PCR system reagents, agarose gel recovery kit, plasmid extraction kit are all purchased from Nanjing Novozyme Co., Ltd.; the expression vector pET-Duet-1 plasmid and the expression strain BL21 (DE3) are all from the bacterial library of this laboratory; LB medium, ampicillin, isopropyl-β-D-thiogalactoside (IPTG), Guanidine HCl, Imidazole, Tris-HCl, Na2HPO4, yeast extract, citric acid monohydrate, ammonium sulfate, potassium dihydrogen phosphate, ferrous sulfate heptahydrate, anhydrous calcium chloride, glucose, magnesium sulfate heptahydrate, citric acid monohydrate, ferric chloride hexahydrate, boric acid, manganese sulfate monohydrate, copper sulfate pentahydrate II, sodium molybdate dihydrate, cobalt chloride hexahydrate and zinc chloride are all purchased from Shanghai Bioengineering; PMSF and DTT are purchased from BBI.
[0045] Unless otherwise stated, the experimental methods disclosed in the present invention all adopt conventional techniques in molecular biology and related fields in the art.
[0046] Example 1
[0047] 1. Modular design:
[0048] Based on short peptides that bind to a single specific G protein-coupled receptor (GPCR) (for example, short peptides with known functions such as semaglutide and liraglutide), these modules are then linked together. Linking the same modules can increase the potency of bioactive peptides; linking different modules can achieve multiple bioactive peptides, that is, regulating different sugar metabolism pathways or different G protein-coupled receptors (GPCRs).
[0049] like Figure 1As shown, A, B, and C are single polypeptide modules that bind to GLP-1 receptors, GIP receptors, and GCG receptors. Multiple bioactive peptides of different combinations are obtained by combining the above modules in pairs, for example, the AB-combined multiple bioactive peptides can bind to GLP-1 receptors and GIP receptors, and the AC-combined polypeptides can bind to GLP-1 receptors and GCG receptors.
[0050] The present invention designs a recombinant engineering bacterium for expressing biological polypeptides, constructs a modular recombinant expression method for biologically active peptides, and tries out the system by taking GLP-1 analog molecules as an example.
[0051] Example 2
[0052] 1. First, the sequences of Analogue-1 (a variant of semaglutide, in which the second amino acid X is changed to A, the nucleotide sequence is shown in SEQ ID NO.1, and the amino acid is shown in SEQ ID NO.2), GIP (the nucleotide sequence is shown in SEQ ID NO.3, and the amino acid is shown in SEQ ID NO.4), GCG (the nucleotide sequence is shown in SEQ ID NO.5, and the amino acid is shown in SEQ ID NO.6), and GLP-1 (the nucleotide sequence is shown in SEQ ID NO.7, and the amino acid is shown in SEQ ID NO.8) are synthesized by recombinant DNA technology. Figure 2 Schematic diagram of modular construction of two connected, GLP-1 and GIP assemble to form Analogue-2 (nucleotide sequence as shown in SEQ ID NO.9, amino acid sequence as shown in SEQ ID NO.10), GLP-1 and GCG assemble to form Analogue-3 (nucleotide sequence as shown in SEQ ID NO.11, amino acid as shown in SEQ ID NO.12), GLP-1 and Analogue-1 assemble to form Analogue-4 (nucleotide sequence as shown in SEQ ID NO.13, amino acid as shown in SEQ ID NO.14), Analogue-1 and GIP assemble to form Analogue-5 (nucleotide sequence as shown in SEQ ID NO.15, amino acid as shown in SEQ ID NO.16), Analogue-1 and GCG assemble to form Analogue-6 (nucleotide sequence as shown in SEQ ID NO.17, amino acid as shown in SEQ ID NO.18), and GIP and GCG assemble to form Analogue-7 (nucleotide sequence as shown in SEQ ID NO.19, amino acid as shown in SEQ ID NO.20). NO.20), the amino acid sequences of GIP, GCG, GLP-1, Semaglutide and Analogue-1 are as follows Figure 2 shown.
[0053] 2. Synthesis of plasmid: After synthesizing Analogue2~7 genes, use primers 1 and 2 to PCR pET-Duet-1 to obtain fragment 1, primers 3 and 4 to PCR Analogue-2 to obtain fragment 2, primers 5 and 6 to PCR Analogue-3 to obtain fragment 3, primers 7 and 8 to PCR Analogue-4 to obtain fragment 4, primers 9 and 10 to PCR Analogue-5 to obtain fragment 5, primers 11 and 12 to PCR Analogue-6 to obtain fragment 6, and primers 13 and 14 to PCR Analogue-7 to obtain fragment 7. Fragment 1 was connected to fragments 2.3.4.5.6.7 by Gibson Assembly to form plasmids Analogue2~7, and transformed into BL21 (DE3) to construct engineering bacteria. After sequencing, the sequence of the engineering bacteria was consistent with the designed sequence.
[0054] 3. The above 6 engineered bacteria were cultured for protein induction. A small amount of strains were picked with an inoculation loop and inoculated into 3 ml of LB medium containing 100ug / ml ampicillin, and placed in a shaker at 37°C, 180rpm for overnight growth. Then the overnight grown strains were added to 1L LB medium containing 100ug / ml ampicillin at a ratio of 1:100 (overnight grown strains: LB medium), and grown at 37°C to OD600 = 0.6. Then the bacterial solution was cooled to 30°C, and 0.5mM isopropyl-β-D-thiogalactoside (IPTG) was added to induce expression in a 30°C shaker at 180rpm for 6 hours. The bacterial solution was collected by centrifugation at 4°C, 5000rpm, 8 minutes, the supernatant was discarded, and the precipitate was marked and placed in -20°C.
[0055] The primers involved are shown in Table 1.
[0056] Table 1
[0057] Primer 1 CATGGTATATCTCCTTCTTAAAGTTAAAC Primer 2 TTAACCTAGGCTGCTGCCAC Primer 3 AACTTTAAGAAGGAGATATACCCATGCCGAG Primer 4 GTGGCAGCAGCCTAGGTTAATTACTGTGTTAT Primer 5 AACTTTAAGAAGGAGATATACCCACGCAGAGGGGACATTCAC Primer 6 GTGGCAGCAGCCTAGGTTAATTAAGTATTCATCA Primer 7 AACTTTAAGAAGGAGATATACCCATGCCGAAGGAACTTTCACAA Primer 8 GTGGCAGCAGCCTAGGTTAATTACCCGCGACC Primer 9 AACTTTAAGAAGGAGATATACCCATGCCGAAGGGACTTTCA Primer 10 GTGGCAGCAGCCTAGGTTAATTACTGCGTGATATTGTGT Primer 11 AACTTTAAGAAGGAGATATACCCACGCAGAAGGCACTT Primer 12 GTGGCAGCAGCCTAGGTTAATTATGTGTTCATAAGCCAT Primer 13 AACTTTAAGAAGGAGATATACCTATGCAGAAGG Primer 14 GTGGCAGCAGCCTAGGTTAATTACGTATTCATCAAC
[0058] Example 3
[0059] Analogue 2-7 collected in Example 2 was subjected to soluble and insoluble tests respectively. The specific steps are as follows:
[0060] Lysis buffer A: 1*PBS+0.5%Trition x-100+1mM PMSF;
[0061] Lysis buffer B: 6M Guanidine Hcl+50mM Tris-Hcl+50mM Na2HPO4+8mM midazole+5mM DTT;
[0062] 1. Resuspend the collected induced expression bacterial solution with Lysis buffer A, and then sonicate on ice at 40W for 1min (2s on, 2s off);
[0063] 2. The bacterial solution after ultrasound was centrifuged at 4°C, 15,000 g, for 20 min, and the supernatant was marked as A (soluble protein);
[0064] 3. After centrifugation, the pellet was resuspended in Lysis buffer B, and then sonicated on ice at 30W for 1 min (2s on, 2s off);
[0065] 4. The bacterial solution after ultrasound was centrifuged at 4°C, 15,000 g, for 20 min, and the supernatant was marked as B (for insoluble protein);
[0066] 5. Prepare supernatant B and run SDS-PAGE.
[0067] Figure 3 This is the gel map of the total protein expression of Analogue2 to 7, lane 1: Marker; lane 2: total protein expression of Analogue-2; lane 3: total protein expression of Analogue-3; lane 4: total protein expression of Analogue-4; lane 5: total protein expression of Analogue-5; lane 6: total protein expression of Analogue-6; lane 7: total protein expression of Analogue-7.
[0068] Figure 3 This shows that the designed dual bioactive peptides Analogue 2 to 7 can be expressed using the constructed modular system.
[0069] Figure 4 This is the soluble test gel image of Analogue2~7, Lane 1: Marker; Lane 2: soluble test gel image of Analogue-2; Lane 3: soluble test gel image of Analogue-3; Lane 4: soluble test expression of Analogue-4; Lane 5: soluble test expression of Analogue-5; Lane 6: soluble test expression of Analogue-6; Lane 7: total protein expression of Analogue-7.
[0070] Figure 4 This indicates that the designed dual bioactive peptide Analogue2-7 can be tested in a soluble form.
[0071] Example 4
[0072] Based on the design of Analogue-2, Analogue-3, Analogue-4, Analogue-5, Analogue-6 and Analogue-7 in Example 2, 6-His tags were added to their N-termini and expressed in Escherichia coli BL21 (DE3), and the corresponding Analogue-2, Analogue-3, Analogue-4, Analogue-5, Analogue-6, Analogue-7 dual polypeptides were extracted and purified using nickel affinity chromatography. The functions of the purified 6 dual GLP-1 proteins were detected by stimulating HEK293A cells and detecting the corresponding cAMP accumulation.
[0073] cAMP content assay activity: For GIPR, GLP-1R and GCGR, cAMP accumulation stimulated by multi-target agonists was measured by LANCE Ultra cAMP kit (PerkinElmer). HEK293A cells were seeded in 6-well plates and cultured in DMEM medium containing 10% (V / V) fetal bovine serum in an incubator at 37°C and 5% CO2. The optimal transfection state was reached when the cells were 60% confluent. Cell transfection was performed according to the Lipofectamine 2000 reagent operating instructions. After 5 hours of transfection, the medium was replaced with DMEM medium containing 5% (V / V) fetal bovine serum. The cells were cultured for 24 hours. After screening, HEK293A cells containing GFP that stably expressed GLP-1R, GFP, and GCGR were obtained. HEK293 cells that are growing well were resuspended and diluted with an appropriate amount of reaction buffer, and the cell density was 3000 cells / well inoculated into a 384-well microtiter plate in HBSS supplemented with 5mM HEPES, 0.1% (w / v) BSA or 0.1% (w / v) casein and 0.5mM 3-isobutyl-1-methylxanthine. According to the requirements of the cAMP detection kit, 5μL of each sample solution to be tested was added to each well of the 384-well microtiter plate, sealed with a transparent sealing film, and placed at room temperature to stimulate the cells for 40 minutes, then Eu-cAMP tracer and ULightTM-anti-cAMP were diluted with cAMP detection buffer and added to the plate to terminate the reaction. The plate was incubated at room temperature for 1 hour, and the reading was recorded in a Tecan microplate reader, and the fluorescence concentration was measured at 665nm and 620nm, and the measured values were plotted.
[0074] Figure 5-10 is the cumulative amount of cAMP of Analogue2~7. It can be seen from the figure that the designed dual bioactive peptides Analogue2~7 can promote the biological activity of releasing cAMP from corresponding multiple targets, which is consistent with the design theory.
[0075] Example 5 Method for producing GLP-1 bioactive peptide
[0076] Prepare fermentation medium: 10 g / L yeast extract, 2 g / L citric acid monohydrate, 5 g / L ammonium sulfate, 7 g / L potassium dihydrogen phosphate, 0.08 g / L ferrous sulfate heptahydrate, 0.006 g / L anhydrous calcium chloride, 10 g / L glucose, 1.5 g / L magnesium sulfate heptahydrate and 10 mL / L metal ion solution; wherein the components of the metal ion solution include: 250 g / L citric acid monohydrate, 16 g / L ferric chloride hexahydrate, 0.6 g / L boric acid, 2 g / L manganese sulfate monohydrate, 0.6 g / L copper sulfate pentahydrate II, 0.6 g / L sodium molybdate dihydrate, 0.5 g / L cobalt chloride hexahydrate and 2 g / L zinc chloride.
[0077] Select a single clone and make a 3 ml overnight culture at 37°C and 180 rpm. When the OD600 of the overnight culture reaches about 4, add 3 ml of the overnight culture to a fermentation tank containing 300 ml of fermentation medium.
[0078] According to the formula of the fermentation broth, it was directly prepared in a 1L fermenter (antibiotics, defoamers and metal ion solutions were not added temporarily), the outlet and inlet filters of the fermenter were closed, and sterilized in an autoclave. After sterilization, sterile stock solutions of ampicillin (100 mg / ml), defoamers and metal ion solutions were added respectively. The pH value was adjusted to 7.0 with 25% NaOH. The oxygenation level was set to 25% and controlled by a constant stirrer speed (200-800 rpm). The reactor temperature was set to 37°C, and the temperature was set to 30°C when the OD600 was about 50. The final concentration of IPTG (0.6 mM) was added to induce protein expression. In the exponential feeding stage, a medium containing 70% glucose was used for exponential feeding. When the oxygenation level suddenly increased and the carbon source was exhausted, the fermenter was set for exponential feeding.
[0079] About 25 hours after IPTG induction, stop the fermentation. Collect the cells by centrifugation at 4200g and remove the culture medium. Add 200ml of cell suspension (20mM Tris-HCl) and resuspend the cells at 4℃. Store the resuspended cells at -20℃ for later use.
[0080] After the fermentation and cultivation of recombinant E. coli is completed, the cell suspension stored at -20°C is first placed in a 4°C water bath for rapid thawing, and then the bacteria are collected using a high-speed centrifuge (e.g., 12,000rpm, 10 minutes, 4°C). After removing the supernatant, an appropriate amount of lysis buffer (50mM Tris-HCl, pH 8.0, 150mM NaCl, 1mM EDTA, containing 1mM PMSF and an appropriate amount of protease inhibitor) is added to resuspend the bacteria, and the cells are lysed by ultrasonic disruption (40kHz, pulse 5 seconds, interval 10 seconds, repeated 5 times). After lysis, centrifugation (20000g, 20 minutes, 4°C) is performed to remove cell debris, and the supernatant is collected as a preliminary extract. Next, nickel column affinity chromatography is performed, using a Ni-NTA affinity column pre-equilibrated with 20mM Tris-HCl, pH 8.0, the lysate is loaded, and the mixture is bound at a slow flow rate of 1ml / min at room temperature. The column is then washed with a wash buffer containing 20mM Imidazole to remove non-specific binding proteins, and then the target protein is eluted with an elution buffer containing 250mM Imidazole and the eluate is collected. Next, anion exchange chromatography is performed, using a DEAE-Sepharose or Q-Sepharose column, selecting a suitable medium according to the isoelectric point of the target protein, loading the target protein eluted from the nickel column, and eluting with a gradient elution buffer of 0-500mM NaCl, and collecting the target protein peak. Subsequently, gel filtration chromatography is performed, and a gel filtration medium with an appropriate pore size such as Superdex200 is selected, the target protein eluted from the ion exchange chromatography is loaded, and separated with a buffer of 50mM Tris-HCl, pH8.0, 150mM NaCl, and the target protein peak is collected. Afterwards, the purified target protein is concentrated using an ultrafiltration device (such as MWCO 10kDa) and replaced by dialysis into a 20mM PBS, pH 7.4 buffer, and the dialysis process is performed at 4°C to ensure protein stability. Finally, protein purity was analyzed by SDS-PAGE (12% gel), and multiple GLP-1 biological activities were evaluated using cAMP accumulation assay to confirm the high purity and functionality of the purified protein. The purified GLP-1 protein solution was dispensed into sterile lyophilized tubes and stored in a -80°C refrigerator to maintain protein stability and activity.
[0081] The above method is based on the purification after fermentation in a 300 mL medicine bottle, and 76.4 mg of the target protein can be obtained, with a yield of 254.6 mg / L, which is the highest yield reported for the expression of dual GLP-1 (analogue-5) in bacteria. The above method is based on the purification after fermentation in a 300 mL medicine bottle, and the target protein can be obtained. The specific yield is shown in Table 2.
[0082] Table 2
[0083]
[0084] Comparative Example 1
[0085] The cAMP accumulation of Analogue1 is as follows Fig.11 As shown, it can be seen that Analogue-1 can only promote the biological activity of releasing cAMP at the corresponding GLP-1 target, but cannot promote the biological activity of releasing cAMP at multiple targets.
[0086] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the spirit and scope of the technical solutions of the present invention, which should all be included in the scope of the claims of the present invention.
[0087] synthetic construct
[0088] Sequence Listing
[0089] SEQ ID NO.1
[0090] Artificial sequence
[0091] CACGCAGAGGGTACGTTTACATCGGATGTAAGCTCGTACCTGGAGGGCC
[0092] AAGCTGCTAAGGAGTTCATTGCCTGGCTTGTCCGGGGGCGCGGTSEQ ID NO.2
[0093] HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG
[0094] SEQ ID NO.3
[0095] TACGCTGAAGGTACTTTCATTAGCGACTACAGCATCGCAATGGACAAGAT
[0096] ACATCAACAAGACTTTGTGAATTGGCTGCTTGCCCAGAAAGGAAAAAAA
[0097] AACGATTGGAAACACAATATCACCCAG
[0098] SEQ ID NO.4
[0099] YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ
[0100] SEQ ID NO.5
[0101] CATTCCCAAGGCACCTTCACTTCAGACTACTCGAAGTATTTGGATAGTAG
[0102] ACGGGCTCAGGATTTTGTTCAATGGCTTATGAACACC
[0103] SEQ ID NO.6
[0104] HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
[0105] SEQ ID NO.7
[0106] CATGCAGAAGGCACCTTTACGTCGGACGTGTCGTCATATTTAGAGGGACA
[0107] AGCAGCAAAGGAGTTCATCGCCTGGTTGGTCAAGGGTCGGGGG
[0108] SEQ ID NO.8
[0109] HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG
[0110] SEQ ID NO.9
[0111] CATGCCGAGGGTACATTCACCTCAGATGTATCTTCCTACCTGGAGGGTCA
[0112] GGCCGCTAAGGAATTTATTGCTTGGTTAGTTAAGGGTCGTGGATACGCGG
[0113] AAGGGACATTTATATCTGACTACAGCATTGCAATGGATAAGATTCATCAA
[0114] CAGGATTTCGTAAACTGGTTATTGGCCCAGAAGGGAAAAAAAAATGACT
[0115] GGAAGCATAATATAACACAG
[0116] SEQ ID NO.10
[0117] HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRGYAEGTFISDYSIAMDKIHQQD
[0118] FVNWLLAQKGKKNDWKHNITQ
[0119] SEQ ID NO.11
[0120] CACGCAGAGGGGACATTCACGAGCGACGTGAGTTCGTACTTGGAAGGTC
[0121] AAGCAGCTAAAGAGTTCATTGCCTGGTTGGTGAAAGGGCGTGGACATTCC
[0122] CAAGGTACCTTTACTTCCGACTATTCAAAGTACCTGGACAGCCGTCGTGC
[0123] CCAAGATTTTGTGCAGTGGCTGATGAATACT
[0124] SEQ ID NO.12
[0125] HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRGHSQGTFTSDYSKYLDSRRAQ
[0126] DFVQWLMNT
[0127] SEQ ID NO.13
[0128] CATGCCGAAGGAACTTTCACAAGCGACGTTAGCTCTTACTTGGAGGGGCA
[0129] AGCGGCGAAAGAATTTATTGCATGGCTTGTGAAGGGTCGTGGGCACGCG
[0130] GAAGGTACATTTACGTCTGATGTATCCAGCTATTTAGAGGGCCAAGCCGC
[0131] GAAAGAGTTTATAGCATGGTTAGTACGGGGTCGCGGGSEQ ID NO.14
[0132] HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRGHAEGTFTSDVSSYLEGQAAK
[0133] EFIAWLVRGRG
[0134] SEQ ID NO.15
[0135] CATGCCGAAGGGACTTTCACTTCGGACGTATCTTCGTACCTTGAGGGGCA
[0136] GGCTGCTAAGGAGTTCATCGCCTGGTTAGTTCGCGGACGGGGATACGCCG
[0137] AGGGGACATTTATTAGTGACTACAGTATCGCAATGGACAAAATTCATCAG
[0138] CAGGATTTCGTAAATTGGCTTTTGGCACAGAAAGGTAAAAAAAATGACT
[0139] GGAAACACAATATCACGCAG
[0140] SEQ ID NO.16
[0141] HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGYAEGTFISDYSIAMDKIHQQD
[0142] FVNWLLAQKGKKNDWKHNITQ
[0143] SEQ ID NO.17
[0144] CACGCAGAAGGCACTTTTACCTCTGACGTAAGTAGTTACCTGGAGGGACA
[0145] AGCCGCAAAGGAGTTCATCGCTTGGTTAGTAAGAGGGCGCGGTCACTCTC
[0146] AGGGAACCTTCACCTCGGATTATTCTAAATACCTGGATTCGCGGCGGGCC
[0147] CAAGATTTTGTCCAATGGCTTATGAACACA
[0148] SEQ ID NO.18
[0149] HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGHSQGTFTSDYSKYLDSRRAQ
[0150] DFVQWLMNT
[0151] SEQ ID NO.19
[0152] TATGCAGAAGGTACATTCATATCGGACTATTCTATTGCAATGGACAAAAT
[0153] CCACCAACAAGACTTCGTTAACTGGCTGCTGGCCCAGAAAGGTAAAAAA
[0154] AATGATTGGAAACATAACATTACTCAGCACTCACAGGGCACATTCACGA
[0155] GTGACTACAGTAAATATCTTGATTCGCGTCGTGCGCAGGACTTTGTTCAG
[0156] TGGTTGATGAATACG
[0157] SEQ ID NO.20
[0158] YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQHSQGTFTSD
[0159] YSKYLDSRRAQDFVQWLMNT。
Claims
1. A semaglutide analogue-1 mutant, characterized in that: The semaglutide Analogue-1 mutant is a single amino acid X at the second position of natural semaglutide replaced by A, and the amino acid sequence of the semaglutide Analogue-1 mutant is shown in SEQ ID NO.
2.
2. Use of the semaglutide Analogue-1 mutant according to claim 1 in the preparation of multiple GLP-1 bioactive peptides.
3. A method for expressing a semaglutide Analogue-1 mutant, characterized in that: The Escherichia coli is obtained by transforming a plasmid containing genes of multiple GLP-1 bioactive peptides; the genes of the multiple GLP-1 bioactive peptides are expressed by modularizing short peptides combined with multiple receptors; Among them, the short peptide includes the semaglutide Analogue-1 mutant, and the nucleotide sequence is shown in SEQ ID NO.1; the receptor includes GIP, GCG and GLP-1, the nucleotide sequence of GIP is shown in SEQ ID NO.3, the nucleotide sequence of GCG is shown in SEQ ID NO.5, and the nucleotide sequence of GLP-1 is shown in SEQ ID NO.
7.
4. The expression method according to claim 3, characterized in that: The Escherichia coli is one or more of DH5α, JM109, W3110, and BL21 (DE3).
5. The expression method according to claim 3, characterized in that: The short peptides also include liraglutide.
6. The expression method according to claim 3, characterized in that: The genes of the multiple GLP-1 bioactive peptides include Analogues 2 to 7, the nucleotide sequence of Analogue-1 is shown as SEQ ID NO.1, the nucleotide sequence of GIP is shown as SEQ ID NO.3, the nucleotide sequence of GCG is shown as SEQ ID NO.5, the nucleotide sequence of GLP-1 is shown as SEQ ID NO.7, the nucleotide sequence of Analogue-2 is shown as SEQ ID NO.9, the nucleotide sequence of Analogue-3 is shown as SEQ ID NO.11, the nucleotide sequence of Analogue-4 is shown as SEQ ID NO.13, the nucleotide sequence of Analogue-5 is shown as SEQ ID NO.15, the nucleotide sequence of Analogue-6 is shown as SEQ ID NO.17, and the nucleotide sequence of Analogue-7 is shown as SEQ ID NO.
19.
7. The expression method according to claim 3, characterized in that: The recombination of the gene Analogues 2 to 7 of the multiple GLP-1 bioactive peptides includes: GLP-1 and GIP are assembled into Analogue-2 through recombinant DNA technology, GLP-1 and GCG are assembled into Analogue-3 through recombinant DNA technology, GLP-1 and Analogue-1 are assembled into Analogue-4 through recombinant DNA technology, Analogue-1 and GIP are assembled into Analogue-5 through recombinant DNA technology, Analogue-1 and GCG are assembled into Analogue-6 through recombinant DNA technology, and GIP and GCG are assembled into Analogue-7.
8. The expression method according to claim 3, characterized in that: include, The genes Analogues 2 to 7 of the multiple GLP-1 bioactive peptides are assembled and connected to the plasmid pET-Duet-1 to construct a recombinant plasmid; The constructed recombinant plasmids were co-transformed into E. coli BL21 (DE3) to obtain recombinant strains.
9. A method for producing a GLP-1 bioactive peptide, characterized in that: The method comprises: transferring the activated recombinant bacteria to a fermentation medium at an inoculation rate of 1-3%, adding IPTG with a final concentration of 0.6 mM to induce protein expression when the OD600 is 50 and the temperature is 30°C, adding chloramphenicol, streptomycin, ampicillin and kanamycin as needed, culturing at 30-37°C, 200 r / min, and a cycle of 20-50 hours.
10. The method for producing a GLP-1 bioactive peptide according to claim 8, characterized in that: The fermentation medium comprises 10 g / L yeast extract, 2 g / L citric acid monohydrate, 5 g / L ammonium sulfate, 7 g / L potassium dihydrogen phosphate, 0.08 g / L ferrous sulfate heptahydrate, 0.006 g / L anhydrous calcium chloride, 10 g / L glucose, 1.5 g / L magnesium sulfate heptahydrate and 10 mL / L metal ion solution; wherein the components of the metal ion solution include: 250 g / L citric acid monohydrate, 16 g / L ferric chloride hexahydrate, 0.6 g / L boric acid, 2 g / L manganese sulfate monohydrate, 0.6 g / L copper sulfate pentahydrate II, 0.6 g / L sodium molybdate dihydrate, 0.5 g / L cobalt chloride hexahydrate and 2 g / L zinc chloride.
Citation Information
Cited By
Preparation method of protease cryoelectron microscope sample and structural analysis method of protease
CN121141727A
